TNG908 was evaluated for pharmacodynamic activityand antitumorefficacy in the LN18 MTAP-deleted glioblastoma cellline-derived xenograft model implanted subcutaneously in NOG mice.Following a study to determine the maximum tolerated dose (MTD) inthe NOG mouse strain, oral administration of TNG908 at well-tolerateddoses (10, 30, or 60 mg/kg BID) resulted in dose-proportional plasmaexposures with maximal concentrations observed 1 h after the lastdose as well as dose-dependent PRMT5 inhibition as determined by thereduction of a single SDMA-modified protein (Figure 10A). Here, MTAP is linked to glioblastoma.